Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Current Assets (2016 - 2025)

Avalo Therapeutics' Current Assets history spans 12 years, with the latest figure at $105.3 million for Q4 2025.

  • For Q4 2025, Current Assets fell 24.19% year-over-year to $105.3 million; the TTM value through Dec 2025 reached $105.3 million, down 24.19%, while the annual FY2025 figure was $105.3 million, 24.19% down from the prior year.
  • Current Assets reached $105.3 million in Q4 2025 per AVTX's latest filing, down from $113.8 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $138.9 million in Q4 2024 to a low of $7.5 million in Q2 2023.
  • Average Current Assets over 5 years is $63.4 million, with a median of $54.6 million recorded in 2021.
  • Peak YoY movement for Current Assets: tumbled 74.74% in 2022, then surged 1554.44% in 2024.
  • A 5-year view of Current Assets shows it stood at $61.8 million in 2021, then crashed by 73.46% to $16.4 million in 2022, then plummeted by 48.86% to $8.4 million in 2023, then soared by 1554.44% to $138.9 million in 2024, then decreased by 24.19% to $105.3 million in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Current Assets are $105.3 million (Q4 2025), $113.8 million (Q3 2025), and $115.2 million (Q2 2025).